Illumina shares on the up as Q3 beats expectations
This article was originally published in Clinica
Executive Summary
Illumina’s hardball stance when Roche came knocking seems increasingly justified, with the former beating analyst estimates for the eighth consecutive quarter and its share price 60% higher than Roche’s offer.